CA2980845A1 - Water-soluble prodrugs - Google Patents
Water-soluble prodrugs Download PDFInfo
- Publication number
- CA2980845A1 CA2980845A1 CA2980845A CA2980845A CA2980845A1 CA 2980845 A1 CA2980845 A1 CA 2980845A1 CA 2980845 A CA2980845 A CA 2980845A CA 2980845 A CA2980845 A CA 2980845A CA 2980845 A1 CA2980845 A1 CA 2980845A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- optionally substituted
- halogen atom
- 6alkoxy
- membered monocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*c(c(*)c1*)c(*)c2c1c(O[Al])c(c(*)c(C(*)=O)[o]1)c1c2O* Chemical compound C*c(c(*)c1*)c(*)c2c1c(O[Al])c(c(*)c(C(*)=O)[o]1)c1c2O* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139077P | 2015-03-27 | 2015-03-27 | |
| US62/139,077 | 2015-03-27 | ||
| PCT/IB2016/051706 WO2016157052A1 (en) | 2015-03-27 | 2016-03-25 | Water-soluble prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2980845A1 true CA2980845A1 (en) | 2016-10-06 |
Family
ID=55650622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2980845A Abandoned CA2980845A1 (en) | 2015-03-27 | 2016-03-25 | Water-soluble prodrugs |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10183925B2 (enExample) |
| EP (1) | EP3274346A1 (enExample) |
| JP (3) | JP6630364B2 (enExample) |
| CN (1) | CN107660202B (enExample) |
| CA (1) | CA2980845A1 (enExample) |
| TW (1) | TWI710555B (enExample) |
| WO (1) | WO2016157052A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10183925B2 (en) * | 2015-03-27 | 2019-01-22 | Boston Biomedical, Inc. | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer |
| WO2017164379A1 (ja) | 2016-03-25 | 2017-09-28 | 大日本住友製薬株式会社 | ２－アルキルカルボニルナフト［２，３－ｂ］フラン－４，９－ジオンの関連物質の製造方法、及びその関連物質 |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| CN111295368A (zh) * | 2017-09-22 | 2020-06-16 | 大日本住友制药株式会社 | 化学活化型水溶性前药 |
| US20220304972A1 (en) * | 2019-08-23 | 2022-09-29 | Sumitomo Dainippon Pharma Co., Ltd. | Combination therapy and biomarker indicating efficacy thereof |
| FR3112145A1 (fr) * | 2020-07-03 | 2022-01-07 | Nanotracks Diagnostics | Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations |
| WO2022003181A1 (fr) * | 2020-07-03 | 2022-01-06 | Nanotracks Diagnostics | Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée |
| CN112194598B (zh) * | 2020-10-15 | 2021-12-21 | 郑州猫眼农业科技有限公司 | 3-(叔丁氧基羰基-r氧基羰基甲基-氨基)-丙酸酯的制备方法 |
| EP4431491A4 (en) * | 2021-11-08 | 2025-03-05 | Asahi Kasei Kabushiki Kaisha | CARBONYL COMPOUND, METHOD FOR PRODUCING A CARBONYL COMPOUND, METHOD FOR PRODUCING AN ISOCYANATE COMPOUND AND ISOCYANATE COMPOSITION |
| CN118302407A (zh) * | 2021-11-08 | 2024-07-05 | 旭化成株式会社 | 羰基化合物、羰基化合物的制造方法、异氰酸酯化合物的制造方法以及异氰酸酯组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| CN103402993A (zh) * | 2011-03-04 | 2013-11-20 | 舟山海中洲新生药业有限公司 | 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯 |
| JP2015506990A (ja) * | 2012-02-17 | 2015-03-05 | ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッドＺｈｏｕｓｈａｎ Ｈａｉｚｈｏｎｇｚｈｏｕ Ｘｉｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | ４，９−ジヒドロキシ−ナフト［２，３−ｂ］フラン脂肪族酸エステルの誘導体の水性ナノ粒子懸濁液を調製する方法 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| US10183925B2 (en) * | 2015-03-27 | 2019-01-22 | Boston Biomedical, Inc. | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer |
-
2016
- 2016-03-25 US US15/561,828 patent/US10183925B2/en active Active
- 2016-03-25 WO PCT/IB2016/051706 patent/WO2016157052A1/en not_active Ceased
- 2016-03-25 EP EP16714015.1A patent/EP3274346A1/en not_active Ceased
- 2016-03-25 CA CA2980845A patent/CA2980845A1/en not_active Abandoned
- 2016-03-25 JP JP2017549601A patent/JP6630364B2/ja not_active Expired - Fee Related
- 2016-03-25 TW TW105109636A patent/TWI710555B/zh not_active IP Right Cessation
- 2016-03-25 CN CN201680030052.0A patent/CN107660202B/zh not_active Expired - Fee Related
-
2018
- 2018-11-19 US US16/194,525 patent/US10800752B2/en not_active Expired - Fee Related
-
2019
- 2019-12-06 JP JP2019221478A patent/JP6885999B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-28 US US17/005,597 patent/US11414394B2/en active Active
-
2021
- 2021-05-13 JP JP2021081570A patent/JP2021120401A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10800752B2 (en) | 2020-10-13 |
| US20190084955A1 (en) | 2019-03-21 |
| TW201639824A (zh) | 2016-11-16 |
| JP2020055854A (ja) | 2020-04-09 |
| HK1243079A1 (zh) | 2018-07-06 |
| EP3274346A1 (en) | 2018-01-31 |
| US20200392098A1 (en) | 2020-12-17 |
| WO2016157052A1 (en) | 2016-10-06 |
| CN107660202B (zh) | 2021-12-24 |
| JP6630364B2 (ja) | 2020-01-15 |
| JP2018509441A (ja) | 2018-04-05 |
| US20180111914A1 (en) | 2018-04-26 |
| US10183925B2 (en) | 2019-01-22 |
| CN107660202A (zh) | 2018-02-02 |
| TWI710555B (zh) | 2020-11-21 |
| JP2021120401A (ja) | 2021-08-19 |
| JP6885999B2 (ja) | 2021-06-16 |
| US11414394B2 (en) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11414394B2 (en) | Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid | |
| ES2944573T3 (es) | Antagonistas de TLR7/8 y usos de los mismos | |
| RU2695521C2 (ru) | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение | |
| TW202341983A (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
| EP4110781B1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP6619420B2 (ja) | Ｍｅｔａｐ−２阻害剤としてのピロリジノン誘導体 | |
| TW202547833A (zh) | Tlr7/8拮抗劑及其用途 | |
| EP4110780B1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| CA3108099A1 (en) | Tlr7/8 antagonists and uses thereof | |
| EP3553052A1 (en) | 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer | |
| JP6987125B2 (ja) | 新規２，４，６−三置換ｓ−トリアジン化合物並びにその製造方法および使用 | |
| EA028059B1 (ru) | Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида | |
| US12251394B2 (en) | Methods for the treatment of bladder cancer | |
| CN114555619A (zh) | 用于烟酰胺腺嘌呤二核苷酸的差分调节的化合物和组合物 | |
| EP3686182A1 (en) | Chemically activated water-soluble prodrug | |
| RU2822180C1 (ru) | Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция | |
| HK1243079B (en) | Water-soluble prodrugs | |
| HK40074260B (en) | 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2005023007A (ja) | 複素環化合物およびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210222 |
|
| FZDE | Discontinued |
Effective date: 20231011 |